RESUMEN
Humans form complex societies in which we routinely engage in social decision-making regarding the allocation of resources among ourselves and others. One dimension that characterizes social decision-making in particular is whether to prioritize self-interest or respect for others-proself or prosocial. What causes this individual difference in social value orientation? Recent developments in the social dual-process theory argue that social decision-making is characterized by its underlying domain-general learning systems: the model-free and model-based systems. In line with this "learning" approach, we propose and experimentally test the hypothesis that differences in social preferences stem from which learning system is dominant in an individual. Here, we used a non-social state transition task that allowed us to assess the balance between model-free/model-based learning and investigate its relation to the social value orientations. The results showed that proselfs depended more on model-based learning, whereas prosocials depended more on model-free learning. Reward amount and reaction time analyses showed that proselfs learned the task structure earlier in the session than prosocials, reflecting their difference in model-based/model-free learning dependence. These findings support the learning hypothesis on what makes differences in social preferences and have implications for understanding the mechanisms of prosocial behavior.
Asunto(s)
Relaciones Interpersonales , Conducta Social , Humanos , Toma de Decisiones , Individualidad , AprendizajeRESUMEN
JC polyomavirus (JCPyV) causes progressive multifocal leukoencephalopathy (PML), a demyelinating disease of the central nervous system affecting immunocompromised patients. The study of PML-type JCPyV in vitro has been limited owing to the inefficient propagation of the virus in cultured cells. In this study, we carried out long-term culture of COS-7 cells (designated as COS-IMRb cells) transfected with PML-type M1-IMRb, an adapted viral DNA with a rearranged non-coding control region (NCCR). The JCPyV derived from COS-IMRb cells were characterized by analyzing the viral replication, amount of virus by hemagglutination (HA), production of viral protein 1 (VP1), and structure of the NCCR. HA assays indicated the presence of high amounts of PML-type JCPyV in COS-IMRb cells. Immunostaining showed only a small population of JCPyV carrying COS-IMRb cells to be VP1-positive. Sequencing analysis of the NCCR of JCPyV after long-term culture revealed that the NCCR of M1-IMRb was conserved in COS-IMRb cells without any point mutation. The JCPyV genomic DNA derived from a clone of COS-IMRb-3 cells was detected, via Southern blotting, as a single band of approximately 5.1 kbp without deletion. These findings suggest the potential of using COS-IMRb-3 cells as a useful tool for screening anti-JCPyV drugs.
Asunto(s)
Virus JC/crecimiento & desarrollo , Virus JC/genética , Leucoencefalopatía Multifocal Progresiva/virología , Cultivo de Virus/métodos , Animales , Southern Blotting/métodos , Células COS , Chlorocebus aethiops , Replicación del ADN , ADN Viral/aislamiento & purificación , Hemaglutinación , Humanos , Transfección , Proteínas Virales/genética , Proteínas Virales/metabolismo , Replicación ViralRESUMEN
The UVA and UVB components of sunlight can produce three classes of bipyrimidine DNA photolesions [cyclobutane pyrimidine dimers (CPDs), pyrimidine (6-4) pyrimidone photoproducts (6-4PPs) and related Dewar valence isomers (DewarPPs)]. The UVA/UVB ratio of sunlight is high in winter and low in summer in the Northern Hemisphere. Since UVB radiation produces 6-4PPs and UVA radiation converts them into DewarPPs through photoisomerization, it is expected that there may be differences in the photoisomerization of 6-4PPs between summer and winter, although that has never been documented. To determine that, isolated DNA was exposed to natural sunlight for 8 h in late summer and in winter, and absolute levels of the three classes of photolesions were quantified using calibrated ELISAs. It was found that sunlight produces CPDs and 6-4PPs in DNA at a ratio of about 9:1 and converts approximately 80% of 6-4PPs into DewarPPs within 3 h. Moreover, photoisomerization is more efficient in winter than in late summer after sunlight irradiation for the same duration, at similar solar UV doses and with the same induction level of CPDs. These results demonstrate that seasonal differences in the UVA/UVB ratio influence the efficiency of the photoisomerization of 6-4PPs into DewarPPs.
RESUMEN
Xeroderma pigmentosum (XP) is a genetic disorder associated with defects in nucleotide excision repair, a pathway that eliminates a wide variety of helix-distorting DNA lesions, including ultraviolet-induced pyrimidine dimers. In addition to skin diseases in sun-exposed areas, approximately 25% of XP patients develop progressive neurological disease, which has been hypothesized to be associated with the accumulation of an oxidatively generated type of DNA damage called purine 8,5'-cyclo-2'-deoxynucleoside (cyclopurine). However, that hypothesis has not been verified. In this study, we tested that hypothesis by using the XP group A gene-knockout (Xpa-/-) mouse model. To quantify cyclopurine lesions in this model, we previously established an enzyme-linked immunosorbent assay (ELISA) using a monoclonal antibody (CdA-1) that specifically recognizes 8,5'-cyclo-2'-deoxyadenosine (cyclo-dA). By optimizing conditions, we increased the ELISA sensitivity to a detection limit of Ëone cyclo-dA lesion/106 nucleosides. The improved ELISA revealed that cyclo-dA lesions accumulate with age in the brain tissues of Xpa-/- and of wild-type (wt) mice, but there were significantly more cyclo-dA lesions in Xpa-/- mice than in wt mice at 6, 24 and 29 months of age. These findings are consistent with the long-standing hypothesis that the age-dependent accumulation of endogenous cyclopurine lesions in the brain may be critical for XP neurological abnormalities.
Asunto(s)
Encéfalo/metabolismo , Daño del ADN , Desoxiadenosinas/análisis , Proteína de la Xerodermia Pigmentosa del Grupo A/genética , Xerodermia Pigmentosa/genética , Factores de Edad , Animales , ADN/química , ADN/metabolismo , Reparación del ADN , Modelos Animales de Enfermedad , Ratones , Ratones Noqueados , Pruebas de MutagenicidadRESUMEN
JC polyomavirus (JCPyV) is the causative agent of progressive multifocal leukoencephalopathy (PML), a demyelinating disease of the central nervous system in immunocompromised patients. Archetype JCPyV circulates in the human population. There have been several reports of archetype JCPyV replication in cultured cells, in which propagation was not enough to produce high titers of archetype JCPyV. In this study, we carried out cultivation of the transfected cells with archetype JCPyV DNA MY for more than 2 months to establish COS-7 cells (designated COS-JC cells) persistently producing archetype JCPyV. Moreover, JCPyV derived from COS-JC cells was characterized by analyzing the viral propagation, size of the viral genome, amount of viral DNA, production of viral protein, and structure of the non-coding control region (NCCR). Southern blotting using a digoxigenin-labeled JCPyV probe showed two different sizes of the JCPyV genome in COS-JC cells. For molecular cloning, four of five clones showed a decrease in the size of complete JCPyV genome. Especially, clone No. 10 was generated the large deletion within the Large T antigen. On the other hand, the archetype structure of the NCCR was maintained in COS-JC cells, although a few point mutations occurred. Quantitative PCR analysis of viral DNA in COS-JC cells indicated that a high copy number of archetype JCPyV DNA was replicated in COS-JC cells. These findings suggest that COS-JC cells could efficiently propagate archetype JCPyV MY and offer a useful tool to study persistent infection of archetype JCPyV in a kidney-derived system.
Asunto(s)
Virus JC/crecimiento & desarrollo , Virus JC/genética , Transfección , Cultivo de Virus , Replicación Viral/genética , Animales , Antígenos Virales de Tumores/genética , Secuencia de Bases , Células COS , Proteínas de la Cápside/genética , Proteínas de la Cápside/aislamiento & purificación , Línea Celular , Chlorocebus aethiops , Clonación Molecular , Replicación del ADN , ADN Viral/genética , ADN Viral/aislamiento & purificación , Genoma Viral , Humanos , Leucoencefalopatía Multifocal Progresiva/virología , Mutación Puntual , Carga Viral , Proteínas Virales/genética , Proteínas Virales/metabolismoRESUMEN
JC polyomavirus (JCPyV) is the causative agent of the demyelinating disease of the central nervous system known as progressive multifocal leukoencephalopathy (PML), which occurs in immunocompromised patients. Moreover, patients treated with natalizumab for multiple sclerosis or Crohn disease can develop PML, which is then termed natalizumab-related PML. Because few drugs are currently available for treating PML, many antiviral agents are being investigated. It has been demonstrated that the topoisomerase I inhibitors topotecan and ß-lapachone have inhibitory effects on JCPyV replication in IMR-32 cells. However, both of these drugs have marginal inhibitory effects on virus propagation in JC1 cells according to RT-PCR analysis. In the present study, the inhibitory effect of another topoisomerase I inhibitor, 7-ethy-10-[4-(1-piperidino)-1-piperidino] carbonyloxy camptothecin (CPT11), was assessed by investigating viral replication, propagation, and viral protein 1 (VP1) production in cultured cells. JCPyV replication was assayed using real-time PCR combined with Dpn I treatment in IMR-32 cells transfected with JCPyV DNA. It was found that JCPyV replicates less in IMR-32 cells treated with CPT11 than in untreated cells. Moreover, CPT11 treatment of JCI cells persistently infected with JCPyV led to a dose-dependent reduction in JCPyV DNA and VP1 production. Additionally, the inhibitory effect of CPT11 was found to be stronger than those of topotecan and ß-lapachone. These findings suggest that CPT11 may be a potential anti-JCPyV agent that could be used to treat PML.
Asunto(s)
Antivirales/antagonistas & inhibidores , Camptotecina/antagonistas & inhibidores , Virus JC/efectos de los fármacos , Replicación Viral/efectos de los fármacos , Camptotecina/administración & dosificación , Camptotecina/toxicidad , Línea Celular/efectos de los fármacos , Línea Celular/virología , Proliferación Celular/efectos de los fármacos , Replicación del ADN/efectos de los fármacos , ADN Viral/genética , Relación Dosis-Respuesta a Droga , Humanos , Concentración 50 Inhibidora , Virus JC/genética , Leucoencefalopatía Multifocal Progresiva/tratamiento farmacológico , Naftoquinonas/antagonistas & inhibidores , Reacción en Cadena en Tiempo Real de la Polimerasa/métodos , Inhibidores de Topoisomerasa I/farmacología , Topotecan/antagonistas & inhibidores , Proteínas Virales/efectos de los fármacosRESUMEN
JC polyomavirus (JCPyV) causes progressive multifocal leukoencephalopathy (PML), a fatal demyelinating disease of the central nervous system, in immunocompromised patients. Because no drugs have been approved for treating PML, many antiviral agents are currently being investigated for this purpose. The inhibitory effects of the topoisomerase I inhibitors topotecan and ß-lapachone were assessed by investigating viral replication, propagation and viral protein 1 (VP1) production in cultured cells. JCPyV replication was assayed using the human neuroblastoma cell line IMR-32 transfected with the JCPyV plasmid and RT- PCR combined with Dpn I treatment. Dpn I digests the input plasmid DNA containing methylated adenosine, but not newly replicated JCPyV DNA, in IMR-32 cells. It was found that JCPyV replicates less in IMR-32 cells treated with topotecan or ß-lapachone than in untreated cells. Moreover, drug treatment of JCI cells, which are IMR-32 cells persistently infected with JCPyV, led to a reduction in the amount of JCPyV DNA and population of VP1-positive cells. These results demonstrate that topotecan and ß-lapachone affects JCPyV propagation in human neuroblastoma cell lines, suggesting that topotecan and ß-lapachone could potentially be used to treat PML.
Asunto(s)
Virus JC/efectos de los fármacos , Virus JC/fisiología , Leucoencefalopatía Multifocal Progresiva/tratamiento farmacológico , Leucoencefalopatía Multifocal Progresiva/virología , Neuroblastoma/virología , Inhibidores de Topoisomerasa/farmacología , Antivirales/farmacología , Línea Celular , Proliferación Celular/efectos de los fármacos , Replicación del ADN/efectos de los fármacos , ADN Viral/genética , Humanos , Virus JC/genética , Naftoquinonas/farmacología , Inhibidores de Topoisomerasa I/farmacología , Topotecan/farmacología , Replicación Viral/efectos de los fármacosRESUMEN
It has been difficult to study JCV replication because of its restricted host range. In this study, JCV replication was examined using different clones in 293 cells. RT-PCR assay revealed that large T antigen expression in cells transfected with IMR-32-adapted JCVs was significantly greater than in those transfected with Mad-1 or CY. DNA replication assay and viral load verified that the IMR-32-adapted JCVs were replication-competent in 293 cells, but not Mad-1 or CY JCVs. These results suggest that a 293 culture system with IMR-32-adapted JCVs may be a useful tool for assessing replication of JCV in vitro.
Asunto(s)
Virus JC/fisiología , Riñón/virología , Infecciones por Polyomavirus/virología , Replicación Viral , Línea Celular , Células Epiteliales/virología , Humanos , Virus JC/genética , Riñón/embriología , Carga Viral , Cultivo de VirusRESUMEN
Xeroderma pigmentosum (XP) is a genetic disorder associated with defects in nucleotide excision repair, which eliminates a wide variety of helix-distorting types of DNA damage including sunlight-induced pyrimidine dimers. In addition to skin disease, approximately 30% of XP patients develop progressive neurological disease, which has been hypothesized to be associated with the accumulation of a particular type of oxidatively generated DNA damage called purine 8,5'-cyclo-2'-deoxynucleosides (purine cyclonucleosides). However, there are no currently available methods to detect purine cyclonucleosides in DNA without the need for DNA hydrolysis. In this study, we generated a novel monoclonal antibody (CdA-1) specific for purine cyclonucleosides in single-stranded DNA that recognizes 8,5'-cyclo-2'-deoxyadenosine (cyclo-dA). An immunoassay using CdA-1 revealed a linear dose response between known amounts of cyclo-dA in oligonucleotides and the antibody binding to them. The quantitative immunoassay revealed that treatment with Fenton-type reagents (CuCl(2)/H(2)O(2)/ascorbate) efficiently produces cyclo-dA in DNA in a dose-dependent manner. Moreover, immunofluorescent analysis using CdA-1 enabled the visualization of cyclo-dA in human osteosarcoma cells, which had been transfected with oligonucleotides containing cyclo-dA. Thus, the CdA-1 antibody is a valuable tool for the detection and quantification of cyclo-dA in DNA, and may be useful for characterizing the mechanism(s) underlying the development of XP neurological disease.
Asunto(s)
Desoxiadenosinas/química , Animales , Anticuerpos Monoclonales , Línea Celular Tumoral , Daño del ADN , Regulación de la Expresión Génica , Humanos , Hibridomas , Inmunoensayo , Ratones , Estructura MolecularRESUMEN
JC polyomavirus (JCV) causes progressive multifocal leukoencephalopathy (PML), a fatal demyelinating disease of the central nervous system (CNS) in immunocompromised patients, and particularly in the severe immunosuppression associated with acquired immunodeficiency syndrome (AIDS). HIV-1 can lead to the production of tumor necrosis factor-alpha (TNF-α) in the CNS. Our aim was to examine the effects of TNF-α on JCV gene expression and replication using a human neuroblastoma cell line, IMR-32, transfected with JCV DNA, M1-IMRb. Quantitative RT-PCR analysis of JCV large T antigen and VP1 mRNA, the viral DNA replication assay, and the DNase protection assay were carried out. TNF-α treatment of IMR-32 cells transfected with JCV DNA induced large T antigen mRNA and JCV DNA replication, while other effects on VP1 mRNA expression and virus production were marginal. In addition, ELISA analysis of the nuclear p65 subunit of nuclear factor κB (NF-κB), which is a hallmark of NF-κB pathway activation, of IMR-32 cells upon TNF-α treatment showed that TNF-α treatment activated the NF-κB pathway in IMR-32 cells. Taken together, our results suggest that TNF-α stimulation could induce JCV replication associated with the induction of JCV large T antigen mRNA through the NF-κB pathway in IMR-32 cells transfected with JCV DNA. Our findings may contribute to further understanding of the pathogenesis of AIDS-related PML.
Asunto(s)
Virus JC/fisiología , Neuronas/efectos de los fármacos , Neuronas/virología , Factor de Necrosis Tumoral alfa/metabolismo , Replicación Viral , Línea Celular Tumoral , Perfilación de la Expresión Génica , Humanos , Reacción en Cadena en Tiempo Real de la PolimerasaRESUMEN
The incidence of progressive multifocal leukoencephalopathy (PML) has increased due to the AIDS pandemic, hematological malignancies, and immunosuppressive therapies. Recently, the number of cases of monoclonal antibody-associated PML has increased in patients treated with immunomodulatory drugs such as natalizumab. However, no common consensus regarding PML therapy has been reached in clinical studies. In order to examine the suppression of JC virus (JCV) replication by 3-aminobenzamide (3-AB), a representative PARP-1 inhibitor, a DNA replication assay was carried out using the neuroblastoma cell line IMR-32 and IMR-adapted JCV. The suppression of JCV propagation by 3-AB was also examined using JCI cells, which are a carrier culture producing continuously high JCV titers. The results indicated that PARP-1 inhibitors, such as 3-aminobenzamide (3-AB), suppress JCV replication and propagation significantly in vitro, as judged by DNA replication assay, hemagglutination, and real-time PCR analysis. It has been also shown that 3-AB reduced PARP-1 activity in IMR-32 cells. According to the results of the MTT assay, the enzyme activity of 3-AB-treated cells was slightly lower than that of DMSO-treated cells. However, the significant suppression of JCV propagation is not related to the slight decrease in cell growth. To our knowledge, this is the first report that PARP-1 inhibitor suppresses the replication of JCV significantly in neuroblastoma cell lines via the reduction of PARP-1 activity. Thus, PARP-1 inhibitors also may be a novel therapeutic drug for PML.
Asunto(s)
Antivirales/metabolismo , Benzamidas/metabolismo , Inhibidores Enzimáticos/metabolismo , Virus JC/fisiología , Inhibidores de Poli(ADP-Ribosa) Polimerasas , Replicación Viral , Línea Celular , Supervivencia Celular , Humanos , Virus JC/efectos de los fármacos , Neuronas/virología , Poli(ADP-Ribosa) Polimerasa-1 , Coloración y Etiquetado , Sales de Tetrazolio/metabolismo , Tiazoles/metabolismo , Carga Viral/efectos de los fármacosRESUMEN
The high incidence of progressive multifocal leukoencephalopathy (PML) among individuals with acquired immunodeficiency syndrome (AIDS) is similar to the incidence of other immunocompromised diseases. The pathogenic JC virus (JCV) with rearranged regulatory regions (PML-type) causes PML, a demyelinating disease in the brains of immunocompromised patients. In a previous study, Tat protein, encoded by human immunodeficiency virus type 1 (HIV-1), markedly enhanced the expression of a reporter gene under control of the JCV late promoter. In order to examine the enhancement of JCV replication by Tat protein, the neuroblastoma cell line IMR-32 was used because it enables IMR-32-adapted JCV. The extent of JCV replication in IMR-32 cells treated with Tat protein was significantly higher than that in untreated IMR-32 cells. The enhancement of JCV propagation by Tat protein was also examined using IMR-32-derived JCV producing (JCI) cells which continuously produce JCV. Treatment of JCI cells with Tat protein led to a significant increase in the titers of progeny viruses. It has also been shown that Tat protein leads to a decrease in the expression of purine-rich element binding protein α (Purα) as an important mediator of JCV replication in IMR-32 cells. Thus, it is probable that Tat protein enhances JCV replication in IMR-32 cells via the down-regulation of Purα expression and cell proliferation. To our knowledge, this is the first report that exogenous Tat protein enhances the replication of JCV efficiently in neuroblastoma cell lines.
Asunto(s)
Virus JC/crecimiento & desarrollo , Neuronas/virología , Replicación Viral , Productos del Gen tat del Virus de la Inmunodeficiencia Humana/metabolismo , Línea Celular Tumoral , Humanos , Cultivo de Virus , Productos del Gen tat del Virus de la Inmunodeficiencia Humana/genéticaRESUMEN
Shiga toxin (Stx) binds to globotriaosyl ceramide (Gb3) receptors on the surface of vascular endothelial cells, which is followed by Gb3-dependent endocytosis, and initiates a cascade leading to cell damage. The Gb3 receptor is localized in lipid rafts, in which cholesterol is tightly packed primarily with sphingolipids in a liquid-ordered state. Recent studies have indicated that phosphodiesterase (PDE) type 4 inhibitors enhance the expression of ATP-binding cassette 1 (ABCA1) which promotes cholesterol efflux from non-rafts at the plasma membrane. Here we report that rolipram, a PDE4 inhibitor, reduced the sensitivity to Stx2 of human umbilical vascular endothelial cells in association with increased apolipoproteinA-I (apoA-I)-mediated cholesterol efflux, and shift of some Gb3 molecules from lipid rafts into non-rafts. Although rolipram treatment did not reduce Gb3 content at the plasma membrane and Stx binding to whole cells of HUVECs, it reduced Stx2 endocytosis. Knockdown of ABCA1 by transfection with siRNA ABCA1 in vascular endothelial cells abrogated the protective effect of rolipram on Stx2-exposed cells. Our present results suggest that the expression level of ABCA1 protein is one of critical determinants of Stx sensitivity levels in vascular endothelial cells.
Asunto(s)
Transportadoras de Casetes de Unión a ATP/biosíntesis , Apoptosis , Membrana Celular/química , Células Endoteliales/efectos de los fármacos , Toxina Shiga/toxicidad , Trihexosilceramidas/metabolismo , Transportador 1 de Casete de Unión a ATP , Transportadoras de Casetes de Unión a ATP/antagonistas & inhibidores , Apolipoproteína A-I/metabolismo , Células Cultivadas , Colesterol/metabolismo , Células Endoteliales/metabolismo , Técnicas de Silenciamiento del Gen , Humanos , Microdominios de Membrana/metabolismo , Inhibidores de Fosfodiesterasa/farmacología , ARN Interferente Pequeño/metabolismo , Rolipram/farmacología , Toxina Shiga/metabolismoRESUMEN
Estrogen-DNA adducts are potential biomarkers for assessing the risk and development of estrogen-associated cancers. 4-Hydroxyequilenin (4-OHEN) and 4-hydroxyequilin (4-OHEQ), the metabolites of equine estrogens present in common hormone replacement therapy (HRT) formulations, are capable of producing bulky 4-OHEN-DNA adducts. Although the formation of 4-OHEN-DNA adducts has been reported, their quantitative detection in mammalian cells has not been done. To quantify such DNA adducts, we generated a novel monoclonal antibody (4OHEN-1) specific for 4-OHEN-DNA adducts. The primary epitope recognized is one type of stereoisomers of 4-OHEN-dA adducts and of 4-OHEN-dC adducts in DNA. An immunoassay with 4OHEN-1 revealed a linear dose-response between known amounts of 4-OHEN-DNA adducts and the antibody binding to those adducts, with a detection limit of approximately five adducts/10(8) bases in 1 microg DNA sample. In human breast cancer cells, the quantitative immunoassay revealed that 4-OHEN produces five times more 4-OHEN-DNA adducts than does 4-OHEQ. Moreover, in a mouse model for HRT, oral administration of Premarin increased the levels of 4-OHEN-DNA adducts in various tissues, including the uterus and ovaries, in a time-dependent manner. Thus, we succeeded in establishing a novel immunoassay for quantitative detection of 4-OHEN-DNA adducts in mammalian cells.
Asunto(s)
Anticuerpos Monoclonales/inmunología , Aductos de ADN/inmunología , Ensayo de Inmunoadsorción Enzimática , Envejecimiento , Animales , Especificidad de Anticuerpos , Línea Celular Tumoral , Aductos de ADN/análisis , Aductos de ADN/química , Equilenina/análogos & derivados , Equilenina/química , Equilenina/metabolismo , Equilina/análogos & derivados , Equilina/química , Equilina/metabolismo , Estrógenos Conjugados (USP)/administración & dosificación , Femenino , Humanos , Ratones , Ratones Endogámicos BALB CRESUMEN
OBJECTIVE: Prostate stem cell antigen was originally identified as an overexpressed gene in prostate cancer and its overexpression correlated with disease progression and prognosis. In this study, we investigated the clinical significance and therapeutic potential of prostate stem cell antigen expression in non-small cell lung cancer. METHODS: Prostate stem cell antigen expression was examined by immunohistochemistry in 97 primary tumors and 21 metastatic lymph nodes from non-small cell lung cancer patients who underwent curative resection from January 2001 through March 2003. Therapeutic potential of targeting prostate stem cell antigen was further examined by small interfering RNA method using human lung cancer cell line (A549). RESULTS: Prostate stem cell antigen protein expression was detected in 94 of 97 primary lesions (97%) and all metastatic lymph nodes. Prostate stem cell antigen expression intensity was positively correlated with advanced pathological T-factor and stage (T1 vs. T2-4, P = 0.014; Stage I vs. Stages II-IV, P = 0.029, respectively). The prognosis of patients with low prostate stem cell antigen expression was significantly better than those with high prostate stem cell antigen expression (5-year disease-free survival rate; 90% vs. 53%, P = 0.001). Finally, small interfering RNA-mediated knockdown of prostate stem cell antigen resulted in the inhibition of lung cancer cell growth. CONCLUSIONS: Prostate stem cell antigen is highly expressed in non-small cell lung cancer and may be functionally important for this fatal disease.
Asunto(s)
Biomarcadores de Tumor/análisis , Carcinoma de Pulmón de Células no Pequeñas/metabolismo , Neoplasias Pulmonares/metabolismo , Glicoproteínas de Membrana/biosíntesis , Proteínas de Neoplasias/biosíntesis , Adulto , Anciano , Anciano de 80 o más Años , Antígenos de Neoplasias , Carcinoma de Pulmón de Células no Pequeñas/mortalidad , Carcinoma de Pulmón de Células no Pequeñas/patología , Línea Celular Tumoral , Supervivencia sin Enfermedad , Proteínas Ligadas a GPI , Humanos , Inmunohistoquímica , Estimación de Kaplan-Meier , Neoplasias Pulmonares/mortalidad , Neoplasias Pulmonares/patología , Persona de Mediana Edad , Estadificación de Neoplasias , Pronóstico , Interferencia de ARN , Reacción en Cadena de la Polimerasa de Transcriptasa InversaRESUMEN
The high incidence of progressive multifocal leukoencephalopathy (PML) in AIDS patients compared with many other immunosuppressive diseases suggests that HIV-1 infection is strictly related to the activation of JC virus (JCV) propagation. In this report, propagation of PML-type JCV in COS-7-derived cell lines stably expressing HIV-1 Tat (COS-tat cells) has been examined. In COS-tat cells, production of viral particles and replication of genomic DNA were markedly increased compared to COS-7 cells, as judged by HA and real-time PCR analyses. These results demonstrate that COS-tat cells provide a useful model system for studying HIV-1 Tat-mediated propagation of PML-type JCV.
Asunto(s)
VIH-1/fisiología , Virus JC/crecimiento & desarrollo , Productos del Gen tat del Virus de la Inmunodeficiencia Humana/fisiología , Animales , Células COS , Chlorocebus aethiopsRESUMEN
The immunological explanation for the "hygiene hypothesis" has been proposed to be induction of T helper 1 (Th1) responses by microbial products. However, the protective results of hygiene hypothesis-linked microbial exposures are currently shown to be unlikely to result from a Th1-skewed response. Until now, effect of microbial exposure early in life on airway innate resistance remained unclear. We examined the role of early life exposure to microbes in airway innate resistance to a respiratory pathogen. Specific pathogen-free weanling mice were nasally exposed to the mixture of microbial extracts or PBS (control) every other day for 28 days and intratracheally infected with Streptococcus pneumoniae 10 days after the last exposure. Exposure to microbial extracts facilitated colonization of aerobic gram-positive bacteria, anaerobic microorganisms, and Lactobacillus in the airway, compared with control exposure. In pneumococcal pneumonia, the exposure prolonged mouse survival days by suppressing bacterial growth and by retarding pneumococcal blood invasion, despite significantly low levels of leukocyte recruitment in the lung. Enhancement of airway resistance was associated with a significant decrease in production of leukocyte chemokine (KC) and TNFalpha, and suppression of matrix metalloproteinase (MMP-9) expression/activation with enhancement of tissue inhibitor of MMP (TIMP-3) activation. The exposure increased production of IFN-gamma, IL-4, and monocyte chemoattractant-1 following infection. Furthermore, expression of Toll-like receptor 2, 4, and 9 was promoted by the exposure but no longer upregulated upon pneumococcal infection. Thus, we suggest that hygiene hypothesis is more important in regulating the PMN-dominant inflammatory response than in inducing a Th1-dominant response.
Asunto(s)
Inmunidad Innata/inmunología , Infecciones Neumocócicas/inmunología , Infecciones Neumocócicas/microbiología , Neumonía/inmunología , Neumonía/microbiología , Streptococcus pneumoniae/fisiología , Animales , Líquido del Lavado Bronquioalveolar/inmunología , Movimiento Celular , Quimiocinas/metabolismo , Recuento de Colonia Microbiana , Activación Enzimática , Inmunoglobulina A/inmunología , Pulmón/enzimología , Pulmón/microbiología , Pulmón/patología , Metaloproteinasas de la Matriz/metabolismo , Ratones , Ratones Endogámicos C57BL , Neutrófilos/citología , Neutrófilos/microbiología , Infecciones Neumocócicas/complicaciones , Infecciones Neumocócicas/enzimología , Neumonía/complicaciones , Neumonía/enzimología , Streptococcus pneumoniae/crecimiento & desarrollo , Inhibidor Tisular de Metaloproteinasa-3/metabolismo , Receptores Toll-Like/metabolismoRESUMEN
Pathogenic JCV with rearranged regulatory regions (PML-type) causes PML, a demyelinating disease, in the brains of immunocompromised patients. On the other hand, archetype JCV persistently infecting the kidney is thought to be converted to PML-type virus during JCV replication in the infected host under immunosuppressed conditions. In addition, Tat protein, encoded by HIV-1, markedly enhances the expression of a reporter gene under control of the JCV late promoter. In order to examine the influence of Tat on JCV propagation, we used kidney-derived COS-7 cells, which only permit archetype JCV, and established COS-tat cells, which express HIV-1 Tat stably. We found that the extent of archetype JCV propagation in COS-tat cells is significantly greater than in COS-7 cells. On the other hand, COS-7 cells express SV40 T antigen, which is a strong stimulator of archetype JCV replication. The expression of SV40 T antigen was enhanced by HIV-1 Tat slightly according to real-time RT-PCR, this was not closely related to JCV replication in COS-tat cells. The efficiency of JCV propagation depended on the extent of expression of functional Tat. To our knowledge, this is the first report of increased production of archetype JCV in a culture system using cell lines stably expressing HIV-1 Tat. We propose here that COS-tat cells are a useful tool for studying the role of Tat in archetype JCV replication in the development of PML.
Asunto(s)
Células COS/virología , VIH-1/fisiología , Virus JC/fisiología , Cultivo de Virus/métodos , Replicación Viral/fisiología , Productos del Gen tat del Virus de la Inmunodeficiencia Humana/fisiología , Animales , Antígenos Transformadores de Poliomavirus/biosíntesis , Chlorocebus aethiops , Replicación del ADN , ADN Viral/genética , ADN Viral/metabolismo , Genoma Viral , Humanos , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Proteínas Virales/genética , Proteínas Virales/metabolismoRESUMEN
To get a clue to understand how mutations in the XPD gene result in different skin cancer susceptibilities in patients with xeroderma pigmentosum (XP) or trichothiodystrophy (TTD), a thorough understanding of their nucleotide excision repair (NER) defects is essential. Here, we extensively characterize the possible causes of NER defects in XP-D and in TTD fibroblasts. The 3 XP-D cell strains examined were similarly deficient in repairing UV-induced cyclobutane pyrimidine dimers (CPDs) and (6-4) photoproducts (6-4PPs) from genomic DNA. The severity of NER defects correlated with their UV sensitivities. Possible alterations of TFIIH (which consists of 10 subunits including XPD) were then examined. All XP-D cell strains were normal in their concentrations of TFIIH, and displayed normal abilities to recruit TFIIH to sites of UV-induced DNA damage. However, replication protein A (RPA; single-stranded DNA binding protein) accumulation at DNA damage sites, which probably reflects the in vivo XPD helicase activity of TFIIH, is similarly impaired in all XP-D cell strains. Meanwhile, all 3 TTD cell strains had approximately 50% decreases in cellular TFIIH content. Importantly, 2 of the 3 TTD cell strains, which carry the major XPD mutations found in TTD patients, showed defective recruitment of TFIIH to DNA damage sites. Moreover, RPA accumulation at damage sites was impaired in all TTD cell strains to different degrees, which correlated with the severity of their NER defects. These results demonstrate that XP-D and TTD cells are both deficient in the repair of CPDs and 6-4PPs, but TTD cells have more multiple causes for their NER defects than do XP-D cells. Since TFIIH is a repair/transcription factor, TTD-specific alterations of TFIIH possibly result in transcriptional defects, which might be implication for the lack of increased incidence of skin cancers in TTD patients.
Asunto(s)
Reparación del ADN , Síndromes de Tricotiodistrofia/genética , Proteína de la Xerodermia Pigmentosa del Grupo D/genética , Xerodermia Pigmentosa/genética , Células Cultivadas , Daño del ADN/efectos de la radiación , Ensayo de Inmunoadsorción Enzimática , Fibroblastos/metabolismo , Fibroblastos/efectos de la radiación , Genoma Humano , Humanos , Dímeros de Pirimidina/efectos de la radiación , Tolerancia a Radiación , Proteína de Replicación A/genética , Proteína de Replicación A/metabolismo , Factor de Transcripción TFIIH/genética , Factor de Transcripción TFIIH/metabolismo , Rayos UltravioletaRESUMEN
We recently showed that arginine transport via cationic amino acid transporter 1 (CAT1), which transports arginine, lysine, ornithine, and histidine, is essential for erythropoiesis. In the present study, to confirm the importance of both arginine and CAT1 in erythropoiesis, we investigated the relationship of arginine uptake activity and differentiation and proliferation of blood cells by knockdown of the CAT1 gene using shRNA. Five short hairpin RNA (shRNA)-transfected K562 cell clones, in which the CAT1 mRNA expression level is decreased, and a vector-transfected clone were obtained. The differentiation to erythrocytes and proliferation of K562 cells were decreased by knockdown of CAT1. In addition, the initial uptake rate of [(3)H]arginine was decreased in the shRNA-transfected cell clones. The ratio of differentiation of CAT1-knockdown K562 cells was well correlated with the uptake activity for arginine by the cells (R(2)=0.59). These findings indicate that CAT1 is directly involved in erythropoiesis through supplying arginine to the blood cells.